Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer

被引：0
|
作者：
Bauer, Smadar
Saad, Akram
Greenhouse, Inbal
Rapoport, Anna Ruth
Shahar, Shir
Barnatan, Tania
Satchi-Fainaro, Ronit
Shapira-Frommer, Ronnie
机构：
[1] Sheba Med Ctr, Ramat Gan, Israel
[2] Tel Aviv Univ, Dept Physiol & Pharmacol, Fac Med, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5581
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
    Matulonis, U.
    Richard, P.
    Campos, S.
    Bryan, J.
    Lee, J.
    Kendal, D.
    Krasner, C.
    Berlin, S.
    Roche, M.
    Duska, L.
    Pereira, L.
    Horowitz, N.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S23 - S24
  • [2] Phase II Study of Carboplatin and Pemetrexed for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
    Matulonis, Ursula A.
    Horowitz, Neil S.
    Campos, Susana M.
    Lee, Hang
    Lee, Julie
    Krasner, Carolyn N.
    Berlin, Suzanne
    Roche, Maria R.
    Duska, Linda R.
    Pereira, Lauren
    Kendall, Deborah
    Penson, Richard T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) : 5761 - 5766
  • [3] Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer.
    Matei, Daniela
    Pant, Alok
    Moroney, John William
    Fleming, Gini F.
    Tanner, Edward
    Swetzig, Wendy M.
    Xu, Jiahui
    Cardenas, Horacio
    Kandpal, Manoj
    Gavrilescu, Andreea
    Chen, Siqi
    Kocherginsky, Masha
    Davuluri, Ramana, V
    Zhang, Bin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma
    Selle, F.
    Sevin, E.
    Ray-Coquard, I.
    Mari, V.
    Berton-Rigaud, D.
    Favier, L.
    Fabbro, M.
    Lesoin, A.
    Lortholary, A.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2191 - 2196
  • [5] A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
    Eisenhauer, Eric L.
    Zanagnolo, Vanna
    Cohn, David E.
    Salani, Ritu
    O'Malley, David M.
    Sutton, Gregory
    Callahan, Michael J.
    Cobb, Bobbi
    Fowler, Jeffrey M.
    Copeland, Larry J.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (02) : 262 - 266
  • [6] A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
    Eisenhauer, E.
    Zanagnolo, V.
    Cohn, D.
    Salani, R.
    O'Malley, D.
    Sutton, G.
    Cobb, B.
    Vaughan, M.
    Fowler, J.
    Copeland, L.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S31 - S31
  • [7] Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer
    Ferrandina, G
    Ludovisi, M
    Dagostino, G
    Lorusso, D
    Naldini, A
    Testa, AC
    Paris, I
    Gallotta, V
    Pozzo, C
    Scambia, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 468S - 468S
  • [8] Phase II trial of pembrolizumab with cisplatin and gemcitabine in women with recurrent platinum-resistant ovarian cancer
    Walsh, C.
    Kamrava, M.
    Rogatko, A.
    Li, A. J.
    Cass, I.
    Karlan, B. Y.
    Rimel, B. J.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 16 - 17
  • [9] Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study
    Plaxe, SC
    Blessing, JA
    Bookman, MA
    Creasman, WT
    GYNECOLOGIC ONCOLOGY, 2002, 84 (01) : 32 - 35
  • [10] A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients
    Viens, P
    Petit, T
    Yovine, A
    Bougnoux, P
    Deplanque, G
    Cottu, PH
    Delva, R
    Lotz, JP
    Belle, SV
    Extra, JM
    Cvitkovic, E
    ANNALS OF ONCOLOGY, 2006, 17 (03) : 429 - 436
12345